Executive Engagement Perrigo is actively engaging investors and has announced participation in the Barclays Global Consumer Conference, signaling a strategic focus on high-level financial and business discussions. This presents an opportunity to approach investor relations and corporate strategy stakeholders to discuss partnerships, contract manufacturing, or distribution synergies for OTC, generic Rx, and API offerings.

Board Expansion Recent addition of independent directors indicates a push toward governance improvements and potential strategic pivots. Target the board or governance-aligned executives with value propositions around scalable manufacturing, quality systems, and compliance enhancements that could support Perrigo’s growth in self-care products and nutritional lines.

Financial Milestone Quarterly revenue in the $50–100M range with a recent earnings beat on earnings per share despite a slight revenue dip signals potential willingness to explore efficiency gains and cost-saving partnerships. Propose competitive sourcing, API supply, or contract manufacturing opportunities to optimize margins and support continued profitability.

Leadership Change The resignation of the CEO for personal reasons followed by new independent directors suggests a period of strategic realignment. Engage at senior management levels to present scalable solutions in product commercialization, regulatory affairs, and market access that align with Perrigo’s OTC and generic Rx portfolio.

Technology Enablement Perrigo’s tech stack includes analytics and enterprise platforms (Alteryx, Adobe Analytics, Power Platform, Tableau, Salesforce, ServiceNow, etc.). This indicates a data-driven approach and openness to technology partners for supply chain optimization, digital marketing collaboration, and data-driven demand forecasting to improve product planning and API sourcing.